{"id":745385,"date":"2016-05-05T05:45:00","date_gmt":"2016-05-05T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/"},"modified":"2025-11-07T01:25:53","modified_gmt":"2025-11-07T06:25:53","slug":"merck-announces-first-quarter-2016-financial-results","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/","title":{"rendered":"Merck Announces First-Quarter 2016 Financial Results"},"content":{"rendered":"<ul>\n<li>         First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS          Increased by 5 Percent to $0.89       <\/li>\n<li>         Company Continues to Expect 2016 Full-Year GAAP EPS to be Between          $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be          Between $3.65 and $3.77       <\/li>\n<li>         First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1          Percent, Including a 4 Percent Negative Impact from Foreign Exchange       <\/li>\n<li>         Obtained FDA Approval of ZEPATIER in the Treatment of Chronic          Hepatitis C Genotypes 1 or 4 Infection       <\/li>\n<li>         Advanced KEYTRUDA Development Program\n<ul>\n<li>             sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer           <\/li>\n<li>             Breakthrough Therapy Designation Granted for Classical Hodgkin              Lymphoma           <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced financial results for the first quarter of 2016.\n    <\/p>\n<p>\n      \u201cOur first quarter\u2019s performance sets us on a good course for the year,\u201d<br \/>\n      said Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cWe remain focused on advancing our pipeline and driving the commercial<br \/>\n      success of our key launches and inline medicines and vaccines.\u201d\n    <\/p>\n<p>\n      <b>Financial Summary<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n          <b>First Quarter<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>2016<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Sales\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $9,312\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $9,425\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            GAAP EPS\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.40\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.33\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP EPS that excludes items listed below<sup>1<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.89\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.85\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            GAAP net income<sup>2<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,125\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          953\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP net income that excludes items listed below<sup>1,2<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,492\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,426\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      Non-GAAP (generally accepted accounting principles) earnings per share<br \/>\n      (EPS) of $0.89 for the first quarter exclude acquisition- and<br \/>\n      divestiture-related costs and restructuring costs.\n    <\/p>\n<p>\n      A reconciliation of GAAP to non-GAAP net income and EPS is provided in<br \/>\n      the tables that follow.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n          <b>First Quarter<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2016<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>EPS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $0.40\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $0.33\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Difference<sup>3<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.49\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.52\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP EPS that excludes items listed below<sup>1<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $0.89\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $0.85\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>Net Income<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          GAAP net income<sup>2<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,125\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $953\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Difference\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,367\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,473\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Non-GAAP net income that excludes items listed below<sup>1,2<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $2,492\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $2,426\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>Decrease (Increase) in Net Income Due to Excluded Items:<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl1 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Acquisition- and divestiture-related costs<sup>4<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,423\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,526\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl1 bwvertalignb bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          196\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          225\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,619\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,751\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          (252)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          (278)\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,367\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,473\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>Additional Executive Commentary<\/b>\n    <\/p>\n<p>\n      \u201cBusiness development is a top priority, and we are actively pursuing<br \/>\n      the best external science through licensing or bolt-on acquisitions to<br \/>\n      bolster our pipeline and grow our company,\u201d said Frazier.\n    <\/p>\n<p>\n      \u201cThe Global Human Health business performed well in the first quarter.<br \/>\n      The JANUVIA franchise demonstrated strong growth, and we remain pleased<br \/>\n      with the ongoing launch of KEYTRUDA in markets around the world,\u201d said<br \/>\n      Adam Schechter, president, Global Human Health. \u201cAdditionally, we are<br \/>\n      already seeing positive signs in the launch of ZEPATIER in the United<br \/>\n      States.\u201d\n    <\/p>\n<p>\n      \u201cMerck Research Laboratories advanced several clinical development<br \/>\n      programs in the first quarter of 2016. We continued to accelerate the<br \/>\n      development of KEYTRUDA with an additional supplemental filing in head<br \/>\n      and neck cancer, and by securing a fourth Breakthrough Therapy<br \/>\n      Designation in classical Hodgkin lymphoma,\u201d said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories.\n    <\/p>\n<p>\n      \u201cWe demonstrated strong performance with a leveraged P&amp;L, growing sales<br \/>\n      and EPS, excluding the impact of foreign exchange. We benefited from the<br \/>\n      contribution of new product launches, while continuing to sustain growth<br \/>\n      in our key franchises and driving operational improvements across the<br \/>\n      company,\u201d said Robert Davis, chief financial officer.\n    <\/p>\n<p>\n      <b>Select Business Highlights<\/b>\n    <\/p>\n<p>\n      Worldwide sales were $9.3 billion for the first quarter of 2016, a<br \/>\n      decrease of 1 percent compared with the first quarter of 2015, including<br \/>\n      a 4 percent negative impact from foreign exchange.\n    <\/p>\n<p>\n      The following table reflects sales of the company\u2019s top pharmaceutical<br \/>\n      products, as well as total sales of Animal Health products.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          $ in millions\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n          <b>First Quarter<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n          <b>Change<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n          <b>Change<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>Ex-Exchange<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2016<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2015<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Total Sales\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $9,312\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $9,425\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -1%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          3%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Pharmaceutical\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          8,104\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          8,266\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -2%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl1 bwvertalignb bwalignl bwsinglebottom\">\n          JANUVIA \/ JANUMET\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,412\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,393\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          4%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl1 bwvertalignb bwalignl bwsinglebottom\">\n          ZETIA \/ VYTORIN\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          889\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          887\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          4%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignb bwalignl bwsinglebottom\">\n          GARDASIL \/ GARDASIL 9\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          378\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          359\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          5%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          7%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            PROQUAD, M-M-R II and VARIVAX\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          357\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          348\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          3%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          4%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl5 bwvertalignb bwalignl bwsinglebottom\">\n          REMICADE\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          349\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          501\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -30%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -26%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignb bwalignl bwsinglebottom\">\n          ISENTRESS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          340\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          385\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -12%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -8%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl5 bwvertalignb bwalignl bwsinglebottom\">\n          CUBICIN\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          292\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n          187*\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n          56%*\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n          57%*\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl5 bwvertalignb bwalignl bwsinglebottom\">\n          KEYTRUDA\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          249\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          83\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n          **\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n          **\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignb bwalignl bwsinglebottom\">\n          SINGULAIR\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          237\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          245\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -3%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -1%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl5 bwvertalignb bwalignl bwsinglebottom\">\n          NASONEX\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          229\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          289\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -21%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -19%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Animal Health\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          829\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          829\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          9%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          Other Revenues\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          379\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          330\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          15%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          23%\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      *First quarter of 2015 reflects approximately two months of sales<br \/>\n      following the acquisition of Cubist Pharmaceuticals, Inc. (Cubist) by<br \/>\n      Merck on Jan. 21, 2015. Percentages reflect comparison to full quarter<br \/>\n      of sales in 2016.<br \/>**\u2265 100%\n    <\/p>\n<p>\n      <b>Commercial and Pipeline Highlights<\/b>\n    <\/p>\n<p>\n      During the first quarter of 2016, the company continued to focus on<br \/>\n      advancing its pipeline, and achieved regulatory and clinical milestones<br \/>\n      for multiple products in its portfolio.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Merck advanced its development program for KEYTRUDA (pembrolizumab),<br \/>\n        an anti-PD-1 therapy for the treatment of metastatic non-small cell<br \/>\n        lung cancer (NSCLC) in previously treated patients whose tumors<br \/>\n        express PD-L1, as well as advanced melanoma.<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            The U.S. Food and Drug Administration (FDA) <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Ffda-accepts-supplemental-biologics-license-application-sbla-keytrud-2&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=accepted&amp;index=1&amp;md5=cd435c4e354e05e8f252f4a580f327b4\" rel=\"nofollow\">accepted<\/a><br \/>\n            for review a supplemental Biologics License Application (sBLA) for<br \/>\n            KEYTRUDA for the treatment of patients with recurrent or<br \/>\n            metastatic head and neck squamous cell carcinoma with disease<br \/>\n            progression on or after platinum-containing chemotherapy. The FDA<br \/>\n            granted Priority Review with a PDUFA action date of Aug. 9, 2016;<br \/>\n            the sBLA will be reviewed under the FDA\u2019s Accelerated Approval<br \/>\n            program.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            KEYTRUDA <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-receives-breakthrough-therapy-designation-us-food-and-drug-admi&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=received&amp;index=2&amp;md5=047fec5005c2ca3ce93da62260a65c48\" rel=\"nofollow\">received<\/a><br \/>\n            Breakthrough Therapy Designation from the FDA for the treatment of<br \/>\n            patients with relapsed or refractory classical Hodgkin lymphoma.<br \/>\n            It is the fourth Breakthrough Therapy Designation granted for<br \/>\n            KEYTRUDA.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            The FDA also <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Ffda-accepts-supplemental-biologics-license-application-sbla-keytrud-1&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=accepted&amp;index=3&amp;md5=ab28be181fb026f1886b1571a2e592cd\" rel=\"nofollow\">accepted<\/a><br \/>\n            for review a sBLA for KEYTRUDA to include data from the pivotal<br \/>\n            KEYNOTE-010 study in which KEYTRUDA showed superior overall<br \/>\n            survival compared to chemotherapy in patients with previously<br \/>\n            treated advanced NSCLC whose tumors express PD-L1. In accordance<br \/>\n            with the accelerated approval process, the data from KEYNOTE-010<br \/>\n            was intended to serve as the confirmatory trial for receiving full<br \/>\n            approval, establishing the clinical benefit by demonstrating<br \/>\n            improved survival over standard chemotherapy.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            The KEYTRUDA clinical development program includes patients with<br \/>\n            more than 30 tumor types in more than 250 clinical trials,<br \/>\n            including more than 100 trials that combine KEYTRUDA with other<br \/>\n            cancer treatments. Registration-enabling trials of KEYTRUDA are<br \/>\n            currently enrolling patients with melanoma, NSCLC, head and neck<br \/>\n            cancer, bladder cancer, gastric cancer, colorectal cancer,<br \/>\n            esophageal cancer, breast cancer, ovarian cancer, Hodgkin<br \/>\n            lymphoma, non-Hodgkin lymphoma, multiple myeloma, nasopharyngeal<br \/>\n            cancer, and other tumors, with further trials in planning for<br \/>\n            other cancers.\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        The FDA <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fprescription-medicine-news%2Fmerck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=approved&amp;index=4&amp;md5=ec8788660aaa40b363cbfa245f1612d6\" rel=\"nofollow\">approved<\/a><br \/>\n        ZEPATIER (elbasvir and grazoprevir), a once-daily, fixed-dose<br \/>\n        combination tablet for the treatment of adult patients with chronic<br \/>\n        hepatitis C virus genotype (GT) 1 or GT4 infection, with or without<br \/>\n        ribavirin.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The FDA <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fmerck-announces-fda-acceptance-biologics-license-application-investigational-house-dust&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=accepted&amp;index=5&amp;md5=23b5c5cf3db5b5f71f2c039458de2f3e\" rel=\"nofollow\">accepted<\/a><br \/>\n        for review the Biologics License Application (BLA) for MK-8237, the<br \/>\n        company\u2019s investigational house dust mite sublingual allergy<br \/>\n        immunotherapy tablet.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The Antimicrobial Drugs Advisory Committee of the FDA has scheduled a<br \/>\n        meeting on June 9, 2016 to discuss the BLA for ZINPLAVA<br \/>\n        (bezlotoxumab), an investigational antitoxin for the prevention of <i>Clostridium<br \/>\n        difficile<\/i> (<i>C. difficile<\/i>) infection recurrence, which was <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-announces-fda-acceptance-biologics-license-application-bezlotoxuma&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=accepted&amp;index=6&amp;md5=bef74243ddf9227c2efa335a0bc0edf6\" rel=\"nofollow\">accepted<\/a><br \/>\n        by the FDA for Priority Review with a PDUFA action date of July 23,<br \/>\n        2016.\n      <\/li>\n<\/ul>\n<p>\n      <b>Pharmaceutical Revenue Performance<\/b>\n    <\/p>\n<p>\n      First-quarter pharmaceutical sales declined 2 percent to $8.1 billion,<br \/>\n      including a 4 percent negative impact from foreign exchange. Excluding<br \/>\n      the impact of exchange, growth reflects higher sales in oncology,<br \/>\n      hospital acute care and diabetes. Growth in oncology was driven by<br \/>\n      higher sales of KEYTRUDA as the company continues to launch the product<br \/>\n      with new indications and in new markets. Growth in hospital acute care<br \/>\n      was driven by sales of the Cubist portfolio and sales growth of certain<br \/>\n      inline brands. Pharmaceutical sales also reflect an increase in the<br \/>\n      diabetes franchise of JANUVIA (sitagliptin) and JANUMET (sitagliptin and<br \/>\n      metformin HCl), medicines that help lower blood sugar in adults with<br \/>\n      type 2 diabetes, driven by strong growth in the United States and<br \/>\n      Europe, partially offset by lower sales in emerging markets.\n    <\/p>\n<p>\n      First-quarter pharmaceutical sales reflect a decrease in REMICADE<br \/>\n      (infliximab), a treatment for inflammatory diseases, due to the<br \/>\n      accelerating impact of biosimilar competition in the company\u2019s marketing<br \/>\n      territories in Europe. Pharmaceutical sales also reflect declines in<br \/>\n      NASONEX (mometasone furoate monohydrate), an inhaled nasal<br \/>\n      corticosteroid for the treatment of nasal allergy symptoms, and ZOSTAVAX<br \/>\n      (zoster vaccine live), a vaccine for the prevention of herpes zoster.<br \/>\n      Pharmaceutical sales were unfavorably affected in the first quarter of<br \/>\n      2016 by the company\u2019s reduced operations in Venezuela.\n    <\/p>\n<p>\n      A generic version of NASONEX became available in the United States in<br \/>\n      March 2016; as a result, the company anticipates significant losses of<br \/>\n      future NASONEX sales. Additionally, in June 2016 the company will lose<br \/>\n      U.S. patent protection for CUBICIN (daptomycin for injection), an I.V.<br \/>\n      antibiotic, and significant losses of CUBICIN sales are expected to<br \/>\n      occur thereafter.\n    <\/p>\n<p>\n      <b>Animal Health Revenue Performance<\/b>\n    <\/p>\n<p>\n      Animal Health sales, which totaled $829 million for the first quarter of<br \/>\n      2016, were in line with sales from the first quarter of 2015. Excluding<br \/>\n      the impact of foreign exchange, Animal Health sales grew 9 percent,<br \/>\n      primarily driven by BRAVECTO (fluralaner), a chewable tablet that kills<br \/>\n      fleas and ticks in dogs for up to 12 weeks.\n    <\/p>\n<p>\n      <b>First-Quarter 2016 Expense and Other Information<\/b>\n    <\/p>\n<p>\n      The tables that follow present selected expense information.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"7\">\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          $ in millions\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>Included in expenses for the period<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n          <b>Acquisition-<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n          <b>and<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n          <b>First Quarter<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n          <b>Divestiture-<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc\">\n          <b>Restructuring<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>2016<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>GAAP<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Related Costs<\/b><sup><b>4<\/b><\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>Costs<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Non-GAAP<\/b><sup><b>1<\/b><\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Materials and production\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $3,572\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,386\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $47\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $2,139\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Marketing and administrative\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,318\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,313\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Research and development\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,659\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          35\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          55\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,569\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          91\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          91\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          <b>First Quarter <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>2015<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Materials and production\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $3,569\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,250\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $105\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $2,214\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Marketing and administrative\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,601\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          227\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          36\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,338\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Research and development\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,737\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          63\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1,672\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          82\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          82\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      The gross margin was 61.6 percent for the first quarter of 2016 compared<br \/>\n      to 62.1 percent for the first quarter of 2015, reflecting 15.4 and 14.4<br \/>\n      unfavorable percentage point impacts, respectively, from the<br \/>\n      acquisition- and divestiture-related costs and restructuring costs noted<br \/>\n      above.\n    <\/p>\n<p>\n      Research and development (R&amp;D) expenses, on a non-GAAP basis, were $1.6<br \/>\n      billion in the first quarter of 2016, a 6 percent decrease compared to<br \/>\n      the first quarter of 2015, primarily driven by lower licensing expenses.\n    <\/p>\n<p>\n      <b>Financial Outlook<\/b>\n    <\/p>\n<p>\n      Merck continues to expect its full-year 2016 GAAP EPS to be between<br \/>\n      $1.96 and $2.23. The company has narrowed and raised its full-year 2016<br \/>\n      non-GAAP EPS to be between $3.65 and $3.77, including an approximately 2<br \/>\n      percent negative impact from foreign exchange at mid-April exchange<br \/>\n      rates. The non-GAAP range excludes acquisition- and divestiture-related<br \/>\n      costs and costs related to restructuring programs. The change in the<br \/>\n      non-GAAP EPS range reflects recent favorability in foreign exchange<br \/>\n      rates, partially offset by the earlier than expected entry of a generic<br \/>\n      version of NASONEX in the United States.\n    <\/p>\n<p>\n      At mid-April exchange rates, Merck now anticipates full-year 2016<br \/>\n      revenues to be between $39.0 billion and $40.2 billion, including an<br \/>\n      approximately 2 percent negative impact from foreign exchange.\n    <\/p>\n<p>\n      In addition, the company continues to expect full-year 2016 non-GAAP<br \/>\n      marketing and administrative expenses to be below 2015 levels and R&amp;D<br \/>\n      expenses to be modestly above 2015 levels.\n    <\/p>\n<p>\n      The company continues to anticipate its full-year 2016 non-GAAP tax rate<br \/>\n      will be in the range of 21.5 to 22.5 percent, including a 2016 R&amp;D tax<br \/>\n      credit.\n    <\/p>\n<p>\n      A reconciliation of anticipated 2016 EPS, as reported in accordance with<br \/>\n      GAAP to non-GAAP EPS that excludes certain items, is provided in the<br \/>\n      table below.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          <b>Full Year<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2016<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          $1.96 to $2.23\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Difference<sup>3<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          1.69 to 1.54\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Non-GAAP EPS that excludes items listed below\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          $3.65 to $3.77\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Acquisition- and divestiture-related costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          $4,700 to $4,400\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          900 to 700\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          5,600 to 5,100\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          (900) to (805)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          $4,700 to $4,295\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>Total Employees<\/b>\n    <\/p>\n<p>\n      As of March 31, 2016, Merck had approximately 68,000 employees worldwide.\n    <\/p>\n<p>\n      <b>Earnings Conference Call<\/b>\n    <\/p>\n<p>\n      Investors, journalists and the general public may access a live audio<br \/>\n      webcast of the call today at 8:00 a.m. EDT on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations&amp;index=7&amp;md5=09877749b4ed53e7777dd9076b437872\" rel=\"nofollow\">http:\/\/investors.merck.com\/investors\/webcasts-and-presentations<\/a>.<br \/>\n      Institutional investors and analysts can participate in the call by<br \/>\n      dialing (706) 758-9927 or (877) 381-5782 and using ID code number<br \/>\n      75256428. Members of the media are invited to monitor the call by<br \/>\n      dialing (706) 758-9928 or (800) 399-7917 and using ID code number<br \/>\n      75256428. Journalists who wish to ask questions are requested to contact<br \/>\n      a member of Merck\u2019s Media Relations team at the conclusion of the call.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=8&amp;md5=dcaefcb186ec5513fe9878a574541272\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=Twitter&amp;index=9&amp;md5=405480e6b0d7972985b35aa507f3a040\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=15d3afff78ab45ed554fbdff8eac0d57\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=f3e424d8d0decae297ab2c6a2079fb50\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=12&amp;md5=74c019edc9ae3c60923745410a4b7772\" rel=\"nofollow\">LinkedIn<\/a>.<br \/>\n      You can also follow our Twitter conversation at $MRK.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51336017&amp;newsitemid=20160505005707&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=13&amp;md5=fa615859b559b46fed5bdbb1ddde6aed\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Merck is providing certain 2016 and 2015 non-GAAP<br \/>\n      information that excludes certain items because of the nature of these<br \/>\n      items and the impact they have on the analysis of underlying business<br \/>\n      performance and trends. Management believes that providing this<br \/>\n      information enhances investors\u2019 understanding of the company\u2019s<br \/>\n      performance. This information should be considered in addition to, but<br \/>\n      not in lieu of, information prepared in accordance with GAAP. For<br \/>\n      description of the items, see Table 2a, including the related footnotes,<br \/>\n      attached to this release.\n    <\/p>\n<p>\n      <sup>2<\/sup> Net income attributable to Merck &amp; Co., Inc.\n    <\/p>\n<p>\n      <sup>3<\/sup> Represents the difference between calculated GAAP EPS and<br \/>\n      calculated non-GAAP EPS, which may be different than the amount<br \/>\n      calculated by dividing the impact of the excluded items by the<br \/>\n      weighted-average shares for the period.\n    <\/p>\n<p>\n      <sup>4<\/sup> Includes expenses for the amortization of intangible assets<br \/>\n      and purchase accounting adjustments to inventories recognized as a<br \/>\n      result of acquisitions, intangible asset impairment charges and expense<br \/>\n      or income related to changes in the estimated fair value measurement of<br \/>\n      contingent consideration. Also includes integration, transaction and<br \/>\n      certain other costs related to business acquisitions and divestitures.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"12\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"12\">\n          <b>CONSOLIDATED STATEMENT OF INCOME &#8211; GAAP<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"12\">\n          <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"12\">\n          <b>(UNAUDITED)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"12\">\n          <b>Table 1<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">\n            \u00a0\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"3\">\n          <b>1Q16<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"3\">\n          <b>1Q15<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>% Change<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Sales\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9,312\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9,425\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          -1%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Costs, Expenses and Other\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          Materials and production <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,572\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,569\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          Marketing and administrative <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,318\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,601\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          -11%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          Research and development <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,659\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,737\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          -4%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          Restructuring costs <sup>(2)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          91\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          82\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          11%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          Other (income) expense, net <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          48\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          55\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          -13%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Income Before Taxes\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,624\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,381\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          18%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Income Tax Provision\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          494\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          423\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Net Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,130\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          958\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          18%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Less: Net Income Attributable to Noncontrolling Interests\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Net Income Attributable to Merck &amp; Co., Inc.\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,125\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          953\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\" colspan=\"2\">\n          18%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          Earnings per Common Share Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.40\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.33\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"2\">\n          21%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Average Shares Outstanding Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,795\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,865\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          Tax Rate\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          30.4\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          %\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          30.6\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          %\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      (1) Amounts include the impact of acquisition and divestiture-related<br \/>\n      costs, restructuring costs and certain other items. See accompanying<br \/>\n      tables for details.\n    <\/p>\n<p>\n      (2) Represents separation and other related costs associated with<br \/>\n      restructuring activities under the company&#8217;s formal restructuring<br \/>\n      programs.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>CONSOLIDATED STATEMENT OF INCOME<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>GAAP TO NON-GAAP RECONCILIATION<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>FIRST QUARTER 2016<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>(UNAUDITED)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"19\">\n          <b>Table 2a<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"2\">\n          <b>Acquisition and<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"3\">\n          <b>GAAP<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"2\">\n          <b>Divestiture-<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"2\">\n          <b>Restructuring<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"2\">\n          <b>Adjustment<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"3\">\n          <b>Non-GAAP<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignr\">\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignm bwalignl\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>Related Costs<\/b><sup><b>(1)<\/b><\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignm bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>Costs <\/b><sup><b>(2)<\/b><\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignm bwalignc\">\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>Subtotal<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Sales\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>9,312<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9,312\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Costs, Expenses and Other\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Materials and production\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,572<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,386\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          47\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,433\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,139\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Marketing and administrative\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,318<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,313\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Research and development\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,659<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          35\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          55\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          90\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,569\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>91<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          91\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          91\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          &#8211;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Other (income) expense, net\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>48<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          48\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Income Before Taxes\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,624<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,423\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (196\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,619\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,243\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Income Tax Provision\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>494<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (252\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            <sup>(3)<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          746\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Net Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,130<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,367\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,497\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Less: Net Income Attributable to Noncontrolling Interests\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>5<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Net Income Attributable to Merck &amp; Co., Inc.\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,125<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,367\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n          )\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,492\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          Earnings per Common Share Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>0.40<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.89\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Average Shares Outstanding Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,795<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,795\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          Tax Rate\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>30.4<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>%<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          23.0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          %\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      Merck is providing non-GAAP information that excludes certain items<br \/>\n      because of the nature of these items and the impact they have on the<br \/>\n      analysis of underlying business performance and trends. Management<br \/>\n      believes that providing this information enhances investors&#8217;<br \/>\n      understanding of the company&#8217;s performance. This information should be<br \/>\n      considered in addition to, but not in lieu of, information prepared in<br \/>\n      accordance with GAAP.\n    <\/p>\n<p>\n      (1) Amounts included in materials and production costs reflect $1.1<br \/>\n      billion of expenses for the amortization of intangible assets recognized<br \/>\n      as a result of acquisitions, as well as $24 million of amortization of<br \/>\n      purchase accounting adjustments to inventories as a result of the prior<br \/>\n      year acquisition of Cubist Pharmaceuticals, Inc., and $252 million of<br \/>\n      impairment charges on product intangibles. Amounts included in marketing<br \/>\n      and administrative expenses reflect integration, transaction and certain<br \/>\n      other costs related to business acquisitions, including severance costs<br \/>\n      which are not part of the company&#8217;s formal restructuring programs, as<br \/>\n      well as transaction and certain other costs related to divestitures.<br \/>\n      Amounts included in research and development expenses primarily reflect<br \/>\n      in-process research and development (&#8220;IPR&amp;D&#8221;) impairment charges.\n    <\/p>\n<p>\n      (2) Amounts primarily include employee separation costs and accelerated<br \/>\n      depreciation associated with facilities to be closed or divested related<br \/>\n      to activities under the company&#8217;s formal restructuring programs.\n    <\/p>\n<p>\n      (3) Represents the estimated tax impact on the reconciling items.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"21\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"21\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"21\">\n          <b>FRANCHISE \/ KEY PRODUCT SALES<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"21\">\n          <b>(AMOUNTS IN MILLIONS)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"21\">\n          <b>Table 3<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"14\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2016<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"14\">\n          <b>2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>% Change<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>1Q<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>1Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>3Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>4Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>FY<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>1Q<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">\n          <b>TOTAL SALES<\/b><sup><b>(1)<\/b><\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>9,312<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>9,425<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>9,785<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>10,073<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>10,215<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>39,498<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>-1<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          <b>PHARMACEUTICAL<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,104<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,266<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,564<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,925<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>9,027<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>34,782<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>-2<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Primary Care and Women&#8217;s Health<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Cardiovascular\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Zetia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          612\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          568\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          635\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          633\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          691\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,526\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          8\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Vytorin\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          277\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          320\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          320\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          302\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          308\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,251\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -13\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Diabetes\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Januvia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          906\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          884\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,044\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,014\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          921\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,863\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Janumet\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          506\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          509\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          554\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          562\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          526\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,151\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -1\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          General Medicine &amp; Women&#8217;s Health\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          NuvaRing\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          175\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          166\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          182\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          190\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          193\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          732\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          6\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Implanon \/ Nexplanon\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          137\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          124\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          176\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          151\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          588\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -2\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Dulera\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          113\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          130\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          120\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          133\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          153\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          536\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -13\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Follistim AQ\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          94\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          82\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          95\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          95\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          383\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          16\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Hospital and Specialty<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Hepatitis\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Zepatier\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          50\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">\n          *\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          HIV\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Isentress\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          340\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          385\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          375\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          377\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          374\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,511\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -12\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Hospital Acute Care\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Cubicin<sup>(2)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          292\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          187\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          293\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          325\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          322\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,127\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          56\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Noxafil\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          145\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          117\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          132\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          128\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          487\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          31\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Cancidas\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          133\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          163\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          137\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          573\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -19\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Invanz\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          114\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          132\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          153\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          144\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          569\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -14\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Bridion\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          90\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          85\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          87\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          89\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          92\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          353\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          6\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Primaxin\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          73\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          65\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          88\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          86\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          313\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          13\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Immunology\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Remicade\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          349\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          501\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          455\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          442\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          396\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,794\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -30\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Simponi\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          158\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          169\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          178\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          185\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          690\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          19\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Oncology<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Keytruda\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          249\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          83\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          159\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          214\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          566\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">\n          *\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Emend\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          126\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          122\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          141\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          535\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Temodar\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          66\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          74\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          80\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          83\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          312\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -12\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Diversified Brands<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Respiratory\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Singulair\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          237\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          245\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          212\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          201\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          273\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          931\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -3\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Nasonex\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          229\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          289\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          215\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          121\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          231\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          858\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -21\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">\n          Other\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Cozaar \/ Hyzaar\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          126\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          185\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          189\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          150\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          143\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          667\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -32\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Arcoxia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          123\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          115\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          123\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          471\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -10\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Fosamax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          94\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          96\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          86\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          82\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          359\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -20\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Zocor\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          46\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          49\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          63\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          56\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          49\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          217\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -7\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Vaccines<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Gardasil \/ Gardasil 9\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          378\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          359\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          427\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          625\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          497\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,908\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          ProQuad, M-M-R II and Varivax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          357\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          348\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          358\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          390\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          409\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,505\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          RotaTeq\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          192\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          89\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          160\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          169\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          610\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -2\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Zostavax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          125\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          175\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          149\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          179\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          246\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          749\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -28\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">\n          Pneumovax 23\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          107\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          106\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          138\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          542\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -3\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">\n          <b>Other Pharmaceutical<\/b><sup><b>(3)<\/b><\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,093\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,235\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,274\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,298\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,300\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,105\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -12\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">\n          <b>ANIMAL HEALTH<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>829<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>829<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>840<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>825<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>830<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,324<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>0<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwpadb1 bwvertalignt bwalignl\">\n          <b>Other Revenues<\/b><sup><b>(4)<\/b><\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>379<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>330<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>381<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>323<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>358<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>1,392<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>15<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      * 100% or greater\n    <\/p>\n<p>\n      Sum of quarterly amounts may not equal year-to-date amounts due to<br \/>\n      rounding.\n    <\/p>\n<p>\n      <sup>(1)<\/sup> Only select products are shown.\n    <\/p>\n<p>\n      <sup>(2)<\/sup> First quarter of 2015 reflects approximately two months<br \/>\n      of sales following the acquisition of Cubist Pharmaceuticals, Inc. by<br \/>\n      Merck on Jan. 21, 2015. Percentage reflects comparison to full quarter<br \/>\n      of sales in 2016.\n    <\/p>\n<p>\n      <sup>(3)<\/sup> Includes Pharmaceutical products not individually shown<br \/>\n      above. Other Vaccines sales included in Other Pharmaceutical were $103<br \/>\n      million in the first quarter of 2016 and $78 million, $76 million, $99<br \/>\n      million and $148 million for the first, second, third and fourth<br \/>\n      quarters of 2015, respectively.\n    <\/p>\n<p>\n      <sup>(4)<\/sup> Other revenues are comprised primarily of alliance<br \/>\n      revenue, third-party manufacturing sales and miscellaneous corporate<br \/>\n      revenues, including revenue hedging activities.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160505005707r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>or<br \/>Investors:<br \/>Teri        Loxam, 908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89 Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77 First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C Genotypes 1 or 4 Infection Advanced KEYTRUDA Development Program sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer Breakthrough Therapy Designation Granted for Classical Hodgkin Lymphoma Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2016. \u201cOur first quarter\u2019s performance sets us on a good course for the year,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cWe remain focused on advancing our pipeline and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745385","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces First-Quarter 2016 Financial Results - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces First-Quarter 2016 Financial Results - Merck.com\" \/>\n<meta property=\"og:description\" content=\"First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89 Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77 First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C Genotypes 1 or 4 Infection Advanced KEYTRUDA Development Program sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer Breakthrough Therapy Designation Granted for Classical Hodgkin Lymphoma Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2016. \u201cOur first quarter\u2019s performance sets us on a good course for the year,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cWe remain focused on advancing our pipeline and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2016-financial-results\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2016-financial-results\\\/\",\"name\":\"Merck Announces First-Quarter 2016 Financial Results - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-05-05T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2016-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2016-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2016-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces First-Quarter 2016 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces First-Quarter 2016 Financial Results - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces First-Quarter 2016 Financial Results - Merck.com","og_description":"First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89 Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77 First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C Genotypes 1 or 4 Infection Advanced KEYTRUDA Development Program sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer Breakthrough Therapy Designation Granted for Classical Hodgkin Lymphoma Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2016. \u201cOur first quarter\u2019s performance sets us on a good course for the year,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cWe remain focused on advancing our pipeline and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:53+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/","name":"Merck Announces First-Quarter 2016 Financial Results - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-05-05T05:45:00+00:00","dateModified":"2025-11-07T06:25:53+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2016-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces First-Quarter 2016 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"91f97407-3caa-45ab-ac2b-744e2f3a8b2e","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/05\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745385\/revisions"}],"predecessor-version":[{"id":3674781,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745385\/revisions\/3674781"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745385"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}